Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27080511 | 1.00 | KDM1A (0.45) | KDM1ACAMK2ASRD5A1KDM1BACHE | |
| SCHEMBL27080967 | 1.00 | KDM1A (0.45) | KDM1ACAMK2ASRD5A1KDM1BACHE | |
| SCHEMBL32667464 | 0.95 | KDM1A (0.44) | KDM1ACAMK2ASRD5A1KDM1BACHE | |
| SCHEMBL16793923 | 0.95 | KDM1A (0.44) | KDM1ACAMK2ASRD5A1KDM1BACHE | |
| SCHEMBL29676739 | 0.95 | KDM1A (0.44) | KDM1ACAMK2ASRD5A1KDM1BACHE | |
| Hydrochloric Acid SCHEMBL16793858 | 0.93 | KDM1A (0.46) | KDM1ACAMK2ASRD5A1KDM1BSLC6A2 | |
| SCHEMBL3215208 | 0.89 | KDM1A (0.47) | KDM1ACAMK2ASRD5A1KDM1BSLC6A2 | |
| SCHEMBL29756024 | 0.89 | KDM1A (0.47) | KDM1ACAMK2ASRD5A1KDM1BSLC6A2 | |
| SCHEMBL584522 | 0.89 | KDM1A (0.47) | KDM1ACAMK2ASRD5A1KDM1BSLC6A2 | |
| SCHEMBL784874 | 0.89 | KDM1A (0.47) | KDM1ACAMK2ASRD5A1KDM1BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | MERCK PATENT GMBH (DE) | 2025-09-16 | — | — | US | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4605395-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | Dong-A ST Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| US-12338237-B2 | Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2025-06-24 | — | — | US | disclosed |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4491622-A2 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2016-11-03 | — | — | US | disclosed |
| EP-3080122-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089327-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089327-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| US-8592426-B2 | Aryl-benzocycloalkyl amide derivatives | Hoffmann—La Roche Inc. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, LYN | KDM1A 1676/4885CAMK2A 274/4885SRD5A1 3327/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | KDM1A 405/4885CAMK2A 1474/4885SRD5A1 575/4885 |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | CYP1A1, AHR, CYP1B1 | KDM1A 1082/4885CAMK2A 1778/4885SRD5A1 3600/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | KDM1A 61/4885CAMK2A 987/4885SRD5A1 1346/4885 |
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | BTK, SYK, ABL1 | KDM1A 1526/4885CAMK2A 559/4885SRD5A1 4360/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | KDM1A 2163/4885CAMK2A 419/4885SRD5A1 2020/4885 |
| US-12338237-B2 | Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same | GBA1, GBA2, ASAH2 | KDM1A 4001/4885CAMK2A 3589/4885SRD5A1 1714/4885 |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | KDM1A 2201/4885CAMK2A 407/4885SRD5A1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.